Kalaris Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	98.05	1.64	3.17	3.06
Short-Term Investments	19.93	-	-	-
Cash & Short-Term Investments	117.98	1.64	3.17	3.06
Cash Growth	7098.41%	-48.28%	3.60%	-
Prepaid Expenses	0.83	0.97	0.16	0.84
Total Current Assets	118.81	2.61	3.33	3.9
Property, Plant & Equipment	1.48	-	-	-
Long-Term Deferred Charges	-	3.15	-	-
Other Long-Term Assets	1.45	0.41	-	-
Total Assets	121.74	6.16	3.33	3.9
Accounts Payable	1.28	1.56	2.36	2.75
Accrued Expenses	8.12	2.15	1	2.52
Short-Term Debt	-	19.91	-	-
Current Portion of Leases	0.32	-	-	-
Other Current Liabilities	-	1.09	0.58	0.42
Total Current Liabilities	9.71	24.7	3.94	5.69
Long-Term Debt	-	-	-	3.25
Long-Term Leases	1.13	-	-	-
Other Long-Term Liabilities	32.08	32.08	-	0.26
Total Liabilities	42.92	56.78	3.94	9.21
Common Stock	0	-	-	-
Additional Paid-In Capital	238.81	19.95	2.38	2.42
Retained Earnings	-160	-116.56	-47.39	-32.7
Comprehensive Income & Other	0.01	-	-	-
Total Common Equity	78.81	-96.62	-45.02	-30.27
Shareholders' Equity	78.81	-50.62	-0.61	-5.31
Total Liabilities & Equity	121.74	6.16	3.33	3.9
Total Debt	1.45	19.91	-	3.25
Net Cash (Debt)	116.53	-18.27	3.17	-0.19
Net Cash Per Share	7.63	-13.67	0.52	-0.04
Filing Date Shares Outstanding	22.93	18.7	6.76	4.44
Total Common Shares Outstanding	22.9	6.73	6.76	4.44
Working Capital	109.1	-22.1	-0.61	-1.79
Book Value Per Share	3.44	-14.36	-6.66	-6.81
Tangible Book Value	78.81	-96.62	-45.02	-30.27
Tangible Book Value Per Share	3.44	-14.36	-6.66	-6.81

Source: S&P Capital IQ. Standard template. Financial Sources.